Primary malignant mucosal melanoma of the maxillofacial area by 김형준 et al.
76
ORIGINAL ARTICLE
   This is an open-access article distributed under the terms of the Creative 
Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
CC
Primary malignant mucosal melanoma of the maxillofacial area 
Hyounmin Kim1, Sanghoon Lee2, In-Ho Cha1, Hyung Jun Kim1, Woong Nam1
1Department of Oral and Maxillofacial Surgery, Yonsei University College of Dentistry, Seoul,  
2Oral Oncology Clinic, Research Institute and Hospital, National Cancer Center, Goyang, Korea
Abstract (J Korean Assoc Oral Maxillofac Surg 2021;47:76-81)
Objectives: We aimed to collect and report data from all patients who have been diagnosed with mucosal malignant melanoma to obtain the epidemi-
ology and principles of current treatments.
Materials and Methods: Between January 2008 and December 2018, 20 patients underwent surgery or follow-up observations at Yonsei University 
Dental Hospital. The patients’ clinical information was reviewed retrospectively.
Results: Seventeen of 20 patients had undergone definitive surgery, while only 6 patients received adjuvant radiotherapy or systemic therapy. Eight of 
20 patients, including those that had recurrent lesions, were provided immunotherapy. The 3-year survival for all stages was 50%, with a local recur-
rence rate of 75% and a metastasis rate of 65%.
Conclusion: The overall survival of patients receiving surgical treatment was longer than that of patients who did not undergo surgical resection. 
Eight of 20 patients received immunotherapy as the first-line regimen at our clinic, and those patients exhibited longer overall survival compared to 
patients in reported keynote studies.
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I. Introduction
Malignant melanoma occurs mainly in cutaneous form but 
is very rarely seen in mucosal form. Mucosal melanoma of 
the head and neck composes 0.7% to 0.8% of total malignant 
melanomas and 8% of total malignant melanomas of the head 
and neck1,2. The median age of such patients is 70 years, and 
the incidence rate is twice that of Caucasians’ than that of 
Americans’3. The lesion is very invasive, with a 5-year sur-
vival rate of 25% to 34% with a poorer prognosis than muco-
sal or vulvar form4-7.
Treatment type and prognosis are unclear due to the rar-
ity of the tumor and its short survival period8. However, for 
resectable tumors, the most common treatment is complete 
surgical resection9-11. Adjuvant radiotherapy is recommended 
to prevent local recurrence9,12, but the exact regimen of sur-
vival benefits of definitive/adjuvant systemic therapy are not 
currently reported13.
Since malignant mucosal melanoma of the head and neck 
was first reported by Lincoln in 1885, approximately 1,000 
cases have been published14. This report compares the treat-
ment received by 20 patients diagnosed with malignant 
mucosal melanoma in the head and neck and evaluates the 
effectiveness of immunotherapy.
II. Materials and Methods
This study was approved by the Institutional Review Board 
of Yonsei University Dental Hospital (IRB No. 2-2019-0075) 
and the written informed consent was waived by the IRB. 
Among the 25 patients diagnosed with malignant mucosal 
melanoma who visited Yonsei University Dental Hospital 
from January 2008 to December 2018, the medical records of 
20 were reviewed; the other 5 patients had undergone surgery 
and observation at other clinics or departments. 
The patients’ clinical information of treatment, adjuvant 
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chemotherapy, survival or most recent observation time, pres-
ence or absence of recurrence or metastasis, and age at death 
was obtained retrospectively based on written and electronic 
medical records. 
In the 20 patients who were suspected of cancer and vis-
ited the clinic, incisional biopsy was performed. Computed 
tomography and positron emission tomography imaging was 
conducted on patients confirmed with mucosal malignant 
melanoma to examine the scope of surgery and metastasis. 
All biopsies were reviewed and diagnosed by one or more 
oral pathologists. 
Survival analysis was completed with using the Kaplan–
Meier method, while survival curve comparisons were per-
formed using the log-rank test. The categorical variables were 
compared using the chi-square test, with statistical signifi-
cance assigned at P<0.05. Statistical processing of the data 
was performed with IBM SPSS Statistics (ver. 25.0; IBM, 
Armonk, NY, USA). 
III. Results
1. Patient demographics
The mean age of the patients at first diagnosis was 55.9 
years (range, 31-72 years). The most common area was the 
maxillary alveolus (n=12, 60.0%), and the TNM stage was 
T3N0M0 (n=9, 45.0%). Patient demographics are summa-
rized in Table 1. 
2. Treatment
Seventeen patients diagnosed with resectable locoregion-
ally advanced melanoma underwent surgery, while the other 
3 patients diagnosed with metastatic malignant mucosal 
melanoma were not operated on but instead underwent pal-
liative chemotherapy. Of the 17 patients who underwent sur-
gery, only 6 were provided adjuvant radiotherapy. The rest of 
the patients obtained free or dysplasia-level surgical margin 
or died before the start of radiotherapy. In the case of chemo-
therapy, 6 of the 17 patients undergoing surgery also received 
chemotherapy. In the remaining patients, systemic therapy 
was not performed for the same reasons as for radiotherapy. 
A total of 8 patients was administered immunotherapy, but 
2 ceased immunotherapy due to metastasis to other organs. 
Three patients exhibited disease-free survival of 4 to 22 
months, but treatment was suspended due to critical sys-
temic side effects. Another 2 of these patients showed 4 to 16 
months of disease-free survival with side effects. Treatment 
by patient and stage is summarized in Fig. 1.
Table 1. Patient demographics (n=20)
Variable Value 
Mean age (yr) 55.9 (31-72)
   <60 9 (45.0)
   ≥60 11 (55.0) 
Sex
   Male 13 (65.0)
   Female 7 (35.0)
Primary site
   Upper alveolus 12 (60.0)
   Mandible 3 (15.0)
   Buccal mucosa 2 (10.0)
   Upper lip 1 (5.0)
   Paranasal sinus 1 (5.0)
Stage
   T3N0M0 9 (45.0)
   T3N1M0 1 (5.0)
   T4aN0M0 4 (20.0)
   T4aN1M0 2 (10.0)
   T3/4aN0/1M1 4 (20.0)
Prognostic comorbidity index
   CCI score ≤4 12
>4 1
   Smoking Yes 9
No 9
   Alcohol Yes 9
No 9
Treatment
   Surgery 17 (85.0)
   Adjuvant systemic therapy 6 (30.0)
   Adjuvant radiotherapy 6 (30.0)
(CCI: Charlson comorbidity index)
Values are presented as mean (range), number (%), or number only.
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Fig. 1. Treatment by clinical stage in this study. (Sx: surgery, RTx: 
radiotherapy, CTx: systemic therapy, CCRT: concurrent chemo-
radio therapy)
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3. Survival rates 
The mean overall survival was 44.3 months (range, 1-152 
months). For all stages, the 3-year survival rate was 50%, the 
5-year survival was 32%, the recurrence rate was 75%, and 
the metastasis rate was 65%. For T3N0M0, overall survival 
was 68.5 months (range, 1-152 months), the 3-year recur-
rence rate was 45%, and the metastasis rate was 40%. For 
T3N1M0 at 12 months, these values were 0%, 0%, and 0%, 
respectively. These variables for T4N0M0 were 37.8 months 
(range, 31-50 months), 100%, and 75%, respectively, and for 
T4aN1M0 were 46 months (range, 31-93 months), 100%, 
and 100%. Overall survival and survival rate by stage are 
summarized in Fig. 2 and 3.
4. Immunotherapy
Eight patients were provided immunotherapy as either the 
first line or the second line of defense in parallel with surgical 
treatment. The 3-year survival rate was 41.7%, and the 5-year 
survival rate was 27.8% for all 12 patients with no immuno-
therapy. Within 3 years, the recurrence rate was 16.7% with a 
metastasis rate of 25%. The 3-year recurrence rate and metas-
tasis rate were 25% in all 4 patients with immunotherapy as 
the primary treatment. In addition, the 3-year metastasis rate 
in all 4 patients with secondary treatment of immunotherapy 
after surgical treatment alone or conventional therapy (adju-
vant systematic therapy or concurrent chemo-radio therapy) 
was 25%. Information on patients with immunotherapy and 
their survival rates are summarized in Tables 2 and 3 and 
Fig. 4.
IV. Discussion 
Malignant mucosal melanoma is a rare disease, with a 
prevalence less than 1% of all melanomas including cuta-
neous forms and of less than 10% of all melanomas of the 
head and neck. Although staging of mucosal melanoma is 
challenging due to the lack of clear parameters affecting the 
survival rate, existing TNM staging based on the size of the 





















Fig. 2. Overall survival rate with survival time in this study.
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Fig. 3. Overall survival rate by clinical 
stages with survival time in this study 
(P<0.01).
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Table 2. Partition of immunotherapy among patients and their re-







Conventional therapy  
(n=12, 60.0%) 
41.7 16.7 25.0
Immunotherapy as the 
first line  
(n=4, 20.0%)
21.7 25.0 25.0
Immunotherapy as the 
second line  
(n=4, 20.0%)
100 - 25.0
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all survival and progress-free survival compared to staging 
based on degree of local recurrence, distant metastasis, or 
depth of invasion in cases of sinonasal melanoma. The older 
was the person, the higher was the prevalence rate, with most 
patients in their 70s, a similar age at diagnosis to that of cuta-
neous melanoma15. Most of the epidemiological and clinical 
data in this study were comparable to those reported in the 
literature. Twenty patients with malignant mucosal melanoma 
of the head and neck were analyzed. The average age of the 
patients was 55.9 years, and the oldest was 72 years, with 
an average observation period of 44.3 months (range, 1-152 
months), which is not significantly different from that of 
other published studies. The prevalence of men was higher in 
our clinic compared to studies that reported women to have 
more common outbreaks than men16,17 and reports that there 
was no difference in prevalence between men and women15.
Although no principles of proper management or prognosis 
have been established due to the rarity of the tumor and its 
short survival rate8, radiotherapy is strongly recommended for 
patients with resectable tumors within 6 weeks after complete 
resection9. However, there are no reports on a clear survival 
benefit of systemic therapy1,9-13. In our clinic, surgical resec-
tion was prioritized in patients (n=17, 85.0%) with resect-
able primary lesions without distant metastasis. Patients with 
positive surgical margin or with local recurrence underwent 
radiotherapy. Systemic therapy was performed regardless of 
the surgical margin if node metastases or adjacent invasion 
was present. The mean survival is 49.8 months when accom-
panied by surgical treatment, but it decreased to 12.3 months 
when radiotherapy or systemic therapy including immuno-
therapy was performed without surgical treatment, which is 
the same trend as large-sample reports stating that survival is 
longer when surgical resection is performed18. 
Due to the difficulty in assessing the efficacy of systemic 
therapy and the limitation of excluding distant metastasis in 
most phase II clinical trials, there is no established regimen 
for primary lesions13. In our cases, patients received a dacar-
bazine single regimen and an anti PD-1 agent (pembrolizum-
ab) as adjuvant systemic therapy and an anti CTLA-4 agent 
(ipilimumab) with an anti PD-1 agent (pembrolizumab) for 
advanced and recurrent lesions. Large-scale random trials of 
anti CTLA-4 and anti PD-1 for malignant mucosal melanoma 
Table 3. Characteristics of patients with immunotherapy 
Patient No. Stage
Primary location  
of the tumor
Surgery 
Adj. RTx  
(Gy)
Immunotherapy Survival (mo) 
1 T4aN0M0 Upper alveolus WE 50 Pembrolizumab Censored (93) 
2 T3N1M0 Floor of mouth WE+ND 82.7 Pembrolizumab Alive (12)
3 T4aN1M1 Upper alveolus - - Ipilimumab Death (5) 
4 T3N0M0 Mandible WE - - -
rT4bNxM0 Mandible WE - Pembrolizumab Alive (72)
5 T3N0M0 Upper alveolus WE+ND 50 - -
rT3NxM0 Soft palate WE 39.6 Pembrolizumab Alive (50)
6 T3N0M0 Upper lip (mucosal) WE 60 - -
rT4aN0M0 Mandible WE - Pembrolizumab Alive (152)
7 T4aN1M0 Upper alveolus WE+ND 63.6 Pembrolizumab Death (24)
8 T4aN1M0 Upper alveolus WE+ND 50 Pembrolizumab Alive (36)
(WE: wide excision, ND: neck dissection, Adj.: adjuvant, RTx: radiotherapy)
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Fig. 4. Overall survival rate by treatment 
with survival time in this study (P=0.128).
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of the head and neck have yet to be carried out19, while there 
are several smaller clinical trials reporting on malignant mu-
cosal melanoma of the entire body, including overall survival 
and disease-free survival rates. It was possible to compare 
our hospital’s treatment compared to 11.3 months and 12.1 
months of survival periods and 2.8 months of disease free sur-
vival on average of few small keynote studies of 8 to 16 peo-
ple whom being treated with immunotherapy exclusively20-22.
In our hospital, the average observation period for the 
group of patients (n=12) who did not undergo immunothera-
py was 34.2 months (range, 1-104 months), and the average 
disease-free survival was 31.3 months (range, 1-104 months). 
For patients who underwent immunotherapy as a secondary 
treatment after conventional therapy other than immunother-
apy, the average observation period was 93 months, with a 
disease-free survival of 76 months. For patients who received 
immunotherapy as the primary treatment (n=4), the average 
observation period was 19.3 months, and the disease free sur-
vival was 16.3 months. As seen in the survival curve of Fig. 4, 
use of immunotherapy as a secondary treatment exhibited a 
higher tendency for survival compared to using only system-
atic regimens other than immunotherapy, but the difference 
was not statistically significant. 
V. Conclusion
This report is not a random trial for a particular treatment, 
but a retrospective study of a previously conducted treatment. 
In addition, this report had statistical limitations in analyzing 
treatment methods and their regimens due to small sample 
sizes. In our clinic, surgical resection is the first choice in 
operable patients, and adjuvant therapy is administered based 
on the margin status and permanent pathologic diagnosis. In 
the case of systemic therapy, for which guidelines remain un-
clear, immunotherapy was performed when local recurrence 
or disease progression was diagnosed. In our clinic, overall 
survival was longer when radiotherapy or immunotherapy 
was combined with surgery and was longer than in previous 
reports. This tendency has been improved through develop-
ment of treatments and immunotherapy23. This implies further 
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